Prange Karen sold $138K of ATRC
Prange Karen sold 3,564 shares of AtriCure, Inc. (ATRC) at $38.80 ($0.14M total) on 2026-08-05.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale details (shares, price, total value, and post-transaction holdings). This can marginally influence sentiment but does not change company fundamentals based on the provided text.
Market read
Traders may note the insider sale for sentiment monitoring, but there is no new guidance, trial, deal, or regulatory development in the text.
What to watch
The article does not state whether the sale was part of a 10b5-1 plan (it says no), but it also provides no context on total compensation, tax obligations, or prior sale patterns.
Background
The article is an SEC Form 4 insider transaction disclosure for AtriCure, Inc. (ATRC).
Ticker impact
AtriCure director Prange Karen filed a Form 4 showing an open-market sale of 3,564 shares at $38.80 on 2026-08-05.
Likely limited, with any impact confined to short-term sentiment around the filing date.
The filing is a director open-market sale with no 10b5-1 plan stated, but the article provides no new operational, financial, or regulatory catalyst.
Market effects
No sector-level implications; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Insider sales can be routine liquidity events and may not reflect bearish expectations, especially if driven by pre-set personal financial needs.
Key entities
- issuerAtriCure, Inc.
US-listed company whose director insider sale is disclosed via Form 4.
- insiderPrange Karen
Director who sold 3,564 shares in an open-market transaction on 2026-08-05.